<DOC>
	<DOCNO>NCT00387205</DOCNO>
	<brief_summary>This study rollover study evaluate long term safety pazopanib continue provide pazopanib patient participate GSK sponsor pazopanib study pazopanib available commercially .</brief_summary>
	<brief_title>Study To Assess Long Term Safety Of Pazopanib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Participated complete GSK sponsor pazopanib study remain eligible continued treatment pazopanib lapatinib ( combination therapy ) . Able understand provide write informed consent Women men agree use protocol specific birth control measure The subject treatment relate serious adverse event remain unresolved unstable pazopanib permanently stop previous study intolerate unsuccessful treat cancer If pregnant breast feed Your doctor think would good candidate study Poorly control high blood pressure Subject unwilling unable follow procedure outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>chronic administration</keyword>
	<keyword>monotherapy combination therapy</keyword>
	<keyword>solid</keyword>
	<keyword>lapatinib ( TYKERB , TYVERB )</keyword>
	<keyword>malignant tumor</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>GW786034</keyword>
	<keyword>cancer</keyword>
	<keyword>safety</keyword>
</DOC>